NYU Langone Health: Melanoma trials

The registry lists 11 Melanoma studies with NYU Langone Health as lead sponsor. 2 are open to participants now and 4 have results posted.

Phase 1 4Phase 2 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and RelatlimabRecruitingNCT07504796Phase 2
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingNCT05428007Phase 2
• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results posted
• Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) MelanomaTerminatedNCT03580382Phase 1/2Results posted
• Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results posted
• Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic MelanomaTerminatedNCT01689974Phase 2Results posted
• A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.Active, not recruitingNCT07177638Not applicable
• A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaTerminatedNCT03565406Phase 1
• Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV MelanomaCompletedNCT02983006Phase 1
• Inducing Systemic Immunity and Regressions in Metastatic MelanomaCompletedNCT02350972Phase 1
• Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III MelanomaCompletedNCT00004104Phase 2